27473951|t|Assessing sex-differences and the effect of timing of vaccination on immunogenicity, reactogenicity and efficacy of vaccines in young children: study protocol for an individual participant data meta-analysis of randomised controlled trials
27473951|a|Disease incidence differs between males and females for some infectious or inflammatory diseases. Sex-differences in immune responses to some vaccines have also been observed, mostly to viral vaccines in adults. Little evidence is available on whether sex-differences occur in response to immunisation in infancy even though this is the age group in which most vaccines are administered. Factors other than sex, such as timing or coadministration of other vaccines, can also influence the immune response to vaccination. Individual participant data meta-analysis of randomised controlled trials of vaccines in healthy infants and young children will be conducted. Fully anonymised data from âˆ¼170 randomised controlled trials of v accines for diphtheria, tetanus, Bordetella pertussis, polio, Haemophilus influenzae type B, hepatitis B, Streptococcus pneumoniae, Neisseria meningitidis, measles, mumps, rubella, varicella and rotavirus will be combined for analysis. Outcomes include measures of immunogenicity (immunoglobulins), reactogenicity, safety and disease -specific clinical efficacy. Data from trials of vaccines containing similar components will be combined in hierarchical models and the effect of sex and timing of vaccinations estimated for each outcome separately. Systematic reviews of published estimates of sex-differences cannot adequately answer questions in this field since such comparisons are never the main purpose of a clinical trial, thus a large degree of reporting bias exists in the published literature. Recent improvements in the widespread availability of individual participant data from randomised controlled trials makes it feasible to conduct extensive individual participant data meta-analyses which were previously impossible, thereby reducing the effect of publication or reporting bias on the understanding of the infant immune response. Preliminary results will be available in 2016 with final results available in 2019. No ethics review is required for secondary analyses of anonymised data.
27473951	0	9	Assessing	T052	C1516048
27473951	10	25	sex-differences	T032	C0036866
27473951	34	40	effect	T080	C1280500
27473951	44	50	timing	T079	C0449243
27473951	54	65	vaccination	T061	C0042196
27473951	69	83	immunogenicity	T038	C4277607
27473951	85	99	reactogenicity	T033	C1691781
27473951	104	124	efficacy of vaccines	T033	C3242199
27473951	128	133	young	T079	C0332239
27473951	134	142	children	T100	C0008059
27473951	144	158	study protocol	T170	C2348563
27473951	166	176	individual	T098	C0237401
27473951	177	188	participant	T098	C0679646
27473951	189	193	data	T078	C1511726
27473951	194	207	meta-analysis	T062	C0920317
27473951	211	239	randomised controlled trials	T062	C0206035
27473951	240	247	Disease	T047	C0012634
27473951	248	257	incidence	T081	C0021149
27473951	274	279	males	T032	C0086582
27473951	284	291	females	T032	C0086287
27473951	301	311	infectious	T047	C0009450
27473951	315	336	inflammatory diseases	T047	C1290884
27473951	338	353	Sex-differences	T032	C0036866
27473951	357	373	immune responses	T042	C0301872
27473951	382	390	vaccines	T121,T129	C0042210
27473951	426	440	viral vaccines	T121,T129	C0042742
27473951	444	450	adults	T100	C0001675
27473951	459	467	evidence	T078	C3887511
27473951	471	480	available	T169	C0470187
27473951	492	507	sex-differences	T032	C0036866
27473951	517	525	response	T033	C1704632
27473951	529	541	immunisation	T061	C0020971
27473951	545	552	infancy	T079	C0231330
27473951	577	586	age group	T100	C0027362
27473951	601	609	vaccines	T121,T129	C0042210
27473951	614	626	administered	T169	C1521801
27473951	628	635	Factors	T169	C1521761
27473951	647	650	sex	T032	C1522384
27473951	660	666	timing	T079	C0449243
27473951	670	686	coadministration	T061	C1533734
27473951	696	704	vaccines	T121,T129	C0042210
27473951	715	724	influence	T077	C4054723
27473951	729	744	immune response	T042	C0301872
27473951	748	759	vaccination	T061	C0042196
27473951	761	771	Individual	T098	C0237401
27473951	772	783	participant	T098	C0679646
27473951	784	788	data	T078	C1511726
27473951	789	802	meta-analysis	T062	C0920317
27473951	806	834	randomised controlled trials	T062	C0206035
27473951	838	846	vaccines	T121,T129	C0042210
27473951	858	865	infants	T100	C0021270
27473951	870	875	young	T079	C0332239
27473951	876	884	children	T100	C0008059
27473951	921	925	data	T078	C1511726
27473951	936	964	randomised controlled trials	T062	C0206035
27473951	970	977	accines	T121,T129	C0042210
27473951	982	992	diphtheria	T047	C0012546
27473951	994	1001	tetanus	T047	C0039614
27473951	1003	1023	Bordetella pertussis	T007	C0006017
27473951	1025	1030	polio	T047	C0032371
27473951	1032	1061	Haemophilus influenzae type B	T007	C0121772
27473951	1063	1074	hepatitis B	T047	C0019163
27473951	1076	1100	Streptococcus pneumoniae	T007	C0038410
27473951	1102	1124	Neisseria meningitidis	T007	C0027575
27473951	1126	1133	measles	T047	C0025007
27473951	1135	1140	mumps	T047	C0026780
27473951	1142	1149	rubella	T047	C0035920
27473951	1151	1160	varicella	T047	C0008049
27473951	1165	1174	rotavirus	T005	C0035870
27473951	1196	1204	analysis	T062	C0936012
27473951	1206	1214	Outcomes	T169	C1274040
27473951	1223	1231	measures	T169	C1879489
27473951	1235	1249	immunogenicity	T038	C4277607
27473951	1251	1266	immunoglobulins	T116,T129	C0021027
27473951	1269	1283	reactogenicity	T033	C1691781
27473951	1285	1291	safety	T068	C0036043
27473951	1296	1303	disease	T047	C0012634
27473951	1314	1331	clinical efficacy	T080	C3850123
27473951	1333	1337	Data	T078	C1511726
27473951	1343	1349	trials	T062	C0008976
27473951	1353	1361	vaccines	T121,T129	C0042210
27473951	1381	1391	components	T073	C0449432
27473951	1412	1424	hierarchical	T169	C0699032
27473951	1425	1431	models	T170	C3161035
27473951	1440	1446	effect	T080	C1280500
27473951	1450	1453	sex	T032	C1522384
27473951	1458	1464	timing	T079	C0449243
27473951	1468	1480	vaccinations	T061	C0042196
27473951	1500	1507	outcome	T169	C1274040
27473951	1520	1538	Systematic reviews	T170	C1955832
27473951	1542	1551	published	T057	C0034037
27473951	1565	1580	sex-differences	T032	C0036866
27473951	1599	1615	answer questions	T061	C0508431
27473951	1624	1629	field	T077	C1521738
27473951	1641	1652	comparisons	T052	C1707455
27473951	1672	1679	purpose	T169	C1285529
27473951	1685	1699	clinical trial	T062	C0008976
27473951	1708	1713	large	T081	C0549177
27473951	1714	1720	degree	T081	C0449286
27473951	1724	1733	reporting	T058	C0700287
27473951	1734	1738	bias	T078	C0242568
27473951	1739	1745	exists	T077	C2987476
27473951	1753	1762	published	T057	C0034037
27473951	1763	1773	literature	T170	C0023866
27473951	1782	1794	improvements	T077	C2986411
27473951	1802	1812	widespread	T082	C0205391
27473951	1813	1828	availability of	T169	C0470187
27473951	1829	1839	individual	T098	C0237401
27473951	1840	1851	participant	T098	C0679646
27473951	1852	1856	data	T078	C1511726
27473951	1862	1890	randomised controlled trials	T062	C0206035
27473951	1920	1929	extensive	T080	C0205231
27473951	1930	1940	individual	T098	C0237401
27473951	1941	1952	participant	T098	C0679646
27473951	1953	1957	data	T078	C1511726
27473951	1958	1971	meta-analyses	T062	C0920317
27473951	1983	1993	previously	T079	C0205156
27473951	1994	2004	impossible	T033	C0243095
27473951	2014	2022	reducing	T080	C0392756
27473951	2027	2033	effect	T080	C1280500
27473951	2037	2048	publication	T073,T170	C0034036
27473951	2052	2061	reporting	T058	C0700287
27473951	2062	2066	bias	T078	C0242568
27473951	2074	2087	understanding	T041	C0162340
27473951	2095	2101	infant	T100	C0021270
27473951	2102	2117	immune response	T042	C0301872
27473951	2119	2138	Preliminary results	T078	C1548161
27473951	2147	2156	available	T169	C0470187
27473951	2176	2183	results	T169	C1274040
27473951	2184	2193	available	T169	C0470187
27473951	2203	2205	No	T169	C0332197
27473951	2206	2212	ethics	T078	C0015000
27473951	2213	2219	review	T170	C0282443
27473951	2236	2254	secondary analyses	UnknownType	C0683944
27473951	2269	2273	data	T078	C1511726